AQST Covered Call Strategy
AQST (Aquestive Therapeutics, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST (Aquestive Therapeutics, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $410.1M, a beta of 1.50 versus the broader market, a 52-week range of 2.145-7.55, average daily share volume of 1.7M, a public-listing history dating back to 2018, approximately 142 full-time employees. These structural characteristics shape how AQST stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.50 indicates AQST has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a covered call on AQST?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current AQST snapshot
As of May 15, 2026, spot at $4.22, ATM IV 61.10%, IV rank 10.42%, expected move 17.52%. The covered call on AQST below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this covered call structure on AQST specifically: AQST IV at 61.10% is on the cheap side of its 1-year range, which means a premium-selling AQST covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 17.52% (roughly $0.74 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AQST expiries trade a higher absolute premium for lower per-day decay. Position sizing on AQST should anchor to the underlying notional of $4.22 per share and to the trader's directional view on AQST stock.
AQST covered call setup
The AQST covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AQST near $4.22, the first option leg uses a $4.43 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AQST chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AQST shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $4.22 | long |
| Sell 1 | Call | $4.43 | N/A |
AQST covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
AQST covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on AQST. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on AQST
Covered calls on AQST are an income strategy run on existing AQST stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
AQST thesis for this covered call
The market-implied 1-standard-deviation range for AQST extends from approximately $3.48 on the downside to $4.96 on the upside. A AQST covered call collects premium on an existing long AQST position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether AQST will breach that level within the expiration window. Current AQST IV rank near 10.42% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AQST at 61.10%. As a Healthcare name, AQST options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AQST-specific events.
AQST covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AQST positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AQST alongside the broader basket even when AQST-specific fundamentals are unchanged. Short-premium structures like a covered call on AQST carry tail risk when realized volatility exceeds the implied move; review historical AQST earnings reactions and macro stress periods before sizing. Always rebuild the position from current AQST chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on AQST?
- A covered call on AQST is the covered call strategy applied to AQST (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With AQST stock trading near $4.22, the strikes shown on this page are snapped to the nearest listed AQST chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are AQST covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the AQST covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 61.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AQST covered call?
- The breakeven for the AQST covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current AQST market-implied 1-standard-deviation expected move is approximately 17.52%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on AQST?
- Covered calls on AQST are an income strategy run on existing AQST stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current AQST implied volatility affect this covered call?
- AQST ATM IV is at 61.10% with IV rank near 10.42%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.